Tilray Brands Inc., through its division Tilray Medical, has announced the publication of a scientific study focusing on the pharmacokinetics of THC and CBD formulations. This research provides insights into the bioavailability of different cannabinoid formulations, contributing to the understanding of medical cannabis for therapeutic treatment. The study involved twelve healthy volunteers and compared the bioavailability of Tilray's THC:CBD extract with nabiximols, revealing higher THC and CBD concentrations with the Tilray extract. No serious adverse events were reported, and the results have already been presented. The findings may have implications for clinical use of these formulations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。